Drugs / HIVAC-1e
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00000631 | ? → Dec 1992 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000683 | ? → Jun 1993 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00001026 | ? → Dec 1994 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00002261 | — | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00000630 | ? → Dec 1992 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000746 | ? → Jul 1994 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIVAC-1e | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000631 ↗ |
| Known as | vaccinia-HIV | “the HIVAC-1e (vaccinia-HIV) vaccine expressing the envelope glycoproteins of HIV” NCT00002261 ↗ |
| Modality | Vaccine | “two candidate HIV vaccines, HIVAC-1e and gp160” NCT00000630 ↗ |
| Route | Other | “These immunizations are administered by scarification on the arm” NCT00000683 ↗ |